- In August 2026, BeOne Medicines and Revolution Medicines announced a multi-part collaboration pairing BeOne’s oncology assets with Revolution’s four clinical RAS(ON) inhibitors, alongside a regional rights deal granting BeOne exclusive development and commercialization rights in select Asian markets while Revolution retains rights elsewhere, including Japan and South Korea.
- The arrangement also shifts some late-stage development burden to BeOne, which will fund and run a global registrational Phase 3 study for one RAS(ON) inhibitor, with Revolution eligible for development and sales milestones plus tiered royalties on regional net sales.
- We’ll now examine how BeOne’s commitment to fund a global registrational Phase 3 trial could influence Revolution Medicines’ investment narrative.
Outshine the giants: these 17 early-stage AI stocks could fund your retirement.
Revolution Medicines Investment Narrative Recap
To own Revolution Medicines, you need to believe its RAS(ON) inhibitors can translate into real world cancer treatments across multiple tumor types despite heavy ongoing losses and no current product revenue. The BeOne collaboration helps by offloading one global Phase 3 trial and adding a royalty stream, but it does not remove the near term risk that pivotal RAS(ON) studies or the first daraxonrasib launch timeline disappoint.
The recent Q2 2026 results, with a net loss of US$644.37 million for the quarter and US$1,098.19 million for the first half, are especially relevant here. They highlight how dependent the story still is on converting late stage programs like daraxonrasib and zoldonrasib into approvals and revenue, even as BeOne’s funding and regional rights deal modestly eases part of the development and commercialization burden.
Yet the biggest issue investors should be aware of is how rising losses and future funding needs could interact with...
Read the full narrative on Revolution Medicines (it's free!)
Revolution Medicines' narrative projects $2.3 billion revenue and $402.5 million earnings by 2029. This implies an earnings increase of about $1.8 billion from -$1.4 billion today.
Uncover how Revolution Medicines' forecasts yield a $204.38 fair value, a 5% downside to its current price.
Exploring Other Perspectives
Some of the lowest analysts were already projecting only about US$838.8 million of revenue by 2029 and still no profits, a much more cautious view that could shift again as collaborations like BeOne’s Phase 3 commitment play out.
Explore 5 other fair value estimates on Revolution Medicines - why the stock might be worth over 3x more than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Revolution Medicines research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Revolution Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revolution Medicines' overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com